JPWO2022101303A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022101303A5 JPWO2022101303A5 JP2023528189A JP2023528189A JPWO2022101303A5 JP WO2022101303 A5 JPWO2022101303 A5 JP WO2022101303A5 JP 2023528189 A JP2023528189 A JP 2023528189A JP 2023528189 A JP2023528189 A JP 2023528189A JP WO2022101303 A5 JPWO2022101303 A5 JP WO2022101303A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- combination
- oral
- methoxyurea
- tetrahydrothieno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims 24
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 claims 24
- 239000003112 inhibitor Substances 0.000 claims 23
- AOMXMOCNKJTRQP-UHFFFAOYSA-N 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea Chemical compound C1=CC(NC(=O)NOC)=CC=C1C1=C(CN(C)C)C(C(=O)N(C=2N=NC(OC)=CC=2)C(=O)N2CC=3C(=CC=CC=3F)F)=C2S1 AOMXMOCNKJTRQP-UHFFFAOYSA-N 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 claims 11
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 6
- 229960005309 estradiol Drugs 0.000 claims 6
- 229930182833 estradiol Natural products 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 208000005641 Adenomyosis Diseases 0.000 claims 4
- 201000009273 Endometriosis Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 4
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 4
- 201000009274 endometriosis of uterus Diseases 0.000 claims 4
- 201000010260 leiomyoma Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 3
- 239000000583 progesterone congener Substances 0.000 claims 3
- 238000012423 maintenance Methods 0.000 claims 2
- 208000007106 menorrhagia Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 229960003604 testosterone Drugs 0.000 claims 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112523P | 2020-11-11 | 2020-11-11 | |
| US63/112,523 | 2020-11-11 | ||
| US202163151423P | 2021-02-19 | 2021-02-19 | |
| US63/151,423 | 2021-02-19 | ||
| PCT/EP2021/081304 WO2022101303A1 (en) | 2020-11-11 | 2021-11-10 | Methods of administering relugolix |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549196A JP2023549196A (ja) | 2023-11-22 |
| JPWO2022101303A5 true JPWO2022101303A5 (enExample) | 2024-11-15 |
Family
ID=78709420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528189A Pending JP2023549196A (ja) | 2020-11-11 | 2021-11-10 | レルゴリクスの投与方法 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4243829A1 (enExample) |
| JP (1) | JP2023549196A (enExample) |
| WO (1) | WO2022101303A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202200254T1 (it) | 2016-09-30 | 2022-07-21 | Takeda Pharmaceuticals Co | Metodi di trattamento di fibromi uterini ed endometriosi |
| WO2021069711A1 (en) | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea |
| MX2022015003A (es) | 2020-05-29 | 2023-03-03 | Myovant Sciences Gmbh | Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200506611B (en) | 2003-01-29 | 2006-12-27 | Takeda Pharmaceutical | Thienopyrimidine compounds and use thereof |
| SMT202200255T1 (it) | 2012-09-28 | 2022-07-21 | Takeda Pharmaceuticals Co | Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea |
| FI4233847T3 (fi) | 2015-02-26 | 2024-09-24 | Takeda Pharmaceuticals Co | Metoksiureajohdannaista ja mannitolihiukkasia käsittävä tabletti |
| CA3002791A1 (en) * | 2015-09-01 | 2017-03-09 | Abbvie Inc. | Methods of administering elagolix |
| DK3518932T3 (da) | 2016-09-30 | 2025-01-27 | Takeda Pharmaceuticals Co | Behandling af prostatacancer |
| SMT202200254T1 (it) | 2016-09-30 | 2022-07-21 | Takeda Pharmaceuticals Co | Metodi di trattamento di fibromi uterini ed endometriosi |
| EP3634418A1 (en) * | 2017-06-05 | 2020-04-15 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| WO2019036712A1 (en) * | 2017-08-18 | 2019-02-21 | Abbvie Inc. | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME OR ADENOMYOSIS |
| JP7713934B2 (ja) | 2019-10-10 | 2025-07-28 | スミトモ ファーマ スウィッツァーランド ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶溶媒和形 |
| WO2021069711A1 (en) | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea |
-
2021
- 2021-11-10 WO PCT/EP2021/081304 patent/WO2022101303A1/en not_active Ceased
- 2021-11-10 EP EP21810968.4A patent/EP4243829A1/en active Pending
- 2021-11-10 JP JP2023528189A patent/JP2023549196A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1051179B1 (en) | Anti-estrogen plus progestin containing oral contraceptives | |
| TW200831107A (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| KR101812160B1 (ko) | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 | |
| US11717527B2 (en) | Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen | |
| JP2012502988A (ja) | 月経抑制、避妊、およびホルモン補充療法のための製剤、ならびにその投与方法 | |
| JP2005512995A (ja) | 不安定又は過活動膀胱を治療するための抗ムスカリン剤及びエストロゲンアゴニスト | |
| JPH02502724A (ja) | 避妊を達成する組成物および方法 | |
| JP2005515964A (ja) | ホルモン欠乏症を治療するための治療用組成物 | |
| FI3518933T4 (fi) | Menetelmiä kohtumyooman ja endometrioosin hoitamiseksi | |
| JP2007512291A (ja) | ２種のエストロゲン及び／又はプロゲスチン組成物を含んで成る、２１〜２８日よりも長い期間にわたっての連続ホルモン処理のための医薬製剤 | |
| MX2012011329A (es) | Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometriosis. | |
| FI3634419T3 (fi) | Gonadotropiinia vapauttavan hormonin antagonistin käsittävä annostusohjelma kohdun myoomien hoitamiseksi ja kuukautisten aiheuttaman verenhukan vähentämiseksi | |
| JP2019529574A5 (enExample) | ||
| FI3518932T3 (fi) | Eturauhassyövän hoito | |
| TW202304425A (zh) | 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合 | |
| CA2601773A1 (en) | Compositions of unconjugated estrogens and methods for their use | |
| JP2004519490A (ja) | エキセメスタンによるホルモン依存性異常症の組合せ治療方法 | |
| TW200303194A (en) | Method of treating menorrhagia and/or dysmenorrhoea | |
| KR20060084864A (ko) | 에스트로겐 화합물 및 프로게스테론 화합물로 이루어진호르몬 조성물 | |
| JP2008515909A (ja) | 上昇用量延長サイクル療法を利用するホルモン処置の方法 | |
| US20040142914A1 (en) | Extended transdermal contraceptive regimens | |
| TWI354556B (en) | Use of a combination of an aromatase inhibitor,a p | |
| JPWO2022101303A5 (enExample) | ||
| JP2004529176A (ja) | 頸管熟化を誘導するためのホスホジエステラーゼインヒビターを含む組成物 | |
| TW200904452A (en) | New drospirenone/17β-estradiol regimen, pharmaceutical combination, product and kit for performing this regimen |